HCV reinfection or superinfection

HCV reinfection or superinfection is the clinically important distinction between having encountered HCV before and being protected against a later exposure. The evidence shows that neither anti-HCV antibodies nor an established HCV infection reliably prevents a new infection, including infection with another viral genotype. This possibility is especially consequential when kidneys from HCV-positive donors are offered to HCV-positive recipients: the strategy may reduce waiting time and avoid wasting organs, but it can also transmit a new strain and complicate liver and graft outcomes.

Definition and Diagnostic Boundaries

HCV status is not a single category. Anti-HCV antibodies indicate exposure, whereas detectable HCV RNA indicates active infection; chronic infection is established by the presence of both anti-HCV antibodies and HCV RNA, with molecular assays detecting levels around 15 IU/ml. That distinction matters for reinfection risk because an antibody-positive person may have resolved infection, while an RNA-positive person remains viremic. Neither state should be interpreted as immunity.

The broader disease may also extend beyond the liver. HCV is recognized as a systemic infection capable of inducing renal, autoimmune, and dermatological disease. Mixed cryoglobulinemia, for example, is characterized by manifestations including purpura, arthralgias, neuropathy, hypocomplementemia, and kidney disease; HCV is mainly associated with type II mixed cryoglobulinemia and cryoglobulinemic glomerulonephritis. A new exposure therefore has significance not only because it may alter viral status, but also because HCV-associated immune-complex disease can affect renal function and transplanted organs.

Reinfection Risk in Transplantation

The use of kidneys from HCV-positive donors illustrates the central paradox of HCV reinfection or superinfection. HCV is transmitted through organ transplantation, and transmission rates in early series varied widely, from 14% to 100%. Because HCV-positive kidneys were in danger of being discarded during a severe organ shortage, transplantation into HCV-positive recipients became a possible way to use otherwise unavailable organs while shortening time on the waiting list. Yet a positive recipient was not automatically protected: anti-HCV antibodies do not confer immunity and do not establish whether the recipient is actively viremic.

The danger is not limited to transmission into a previously uninfected recipient. Superinfection with a different HCV genotype may occur even when the recipient already has HCV RNA in the blood. Experimental post-transfusion studies in chimpanzees found that preexisting infection did not protect against reinfection with either a different genotype or the same genotype. Clinical transplant experience supports the same conclusion: a baseline HCV infection does not protect a kidney recipient from acquiring an additional genotype from the donor.

Genotype Matching and Prevention

Because genotype replacement or mixed infection may carry additional risk, the recommended principle is that donor and recipient should have the same HCV genotype whenever possible. This is a practical attempt to reduce the biological uncertainty of superinfection, although it is constrained by the short time available for organ allocation. Genotype matching cannot eliminate every risk, but it narrows the possibility that an HCV-positive kidney will introduce a substantially different viral strain.

The clinical importance of mismatch is illustrated by a report of severe liver disease after transplantation of a kidney from an HCV-positive donor to an HCV-positive recipient whose infections involved different genotypes, genotype 1 and genotype 2. Mixed infection has not generally been associated with increased mortality, but this severe outcome demonstrates why a preexisting diagnosis should not be treated as a blanket guarantee of safety.

Screening, Monitoring, and Institutional Control

The same logic of repeated verification applies outside transplantation. Kidney transplant candidates are screened for anti-HCV antibodies and, where appropriate, active viremia by nucleic acid testing. In low-prevalence settings, enzyme immunoassay may be followed by nucleic acid testing; in high-prevalence settings, nucleic acid testing is recommended as the initial screen because a negative antibody test cannot reliably exclude infection. Patients on the waiting list who test positive by nucleic acid testing are placed on hold and referred for hepatological assessment and possible treatment.

Patients who achieved a sustained virological response before transplantation require at least annual nucleic acid testing to confirm that the response persists. Relapse triggers renewed referral and consideration of retreatment, while patients who remain viremic require annual assessment for progression of liver disease. These procedures show how reinfection and relapse are kept conceptually separate from antibody status: the decisive surveillance tool is detection of HCV RNA, not the mere presence or absence of antibodies.

In hemodialysis, the prevention problem is framed primarily as nosocomial transmission rather than donor-derived superinfection. A systematic review found that failures in infection-control procedures were the probable cause of new HCV cases in the examined outbreaks. The dialysis machine’s internal circuit appeared to play, at most, a small role, and the KDIGO workgroup did not recommend dedicated machines for HCV-infected patients. Separate-unit isolation was likewise not recommended as a substitute for strict infection-control procedures, because large observational studies found no protective effect after adjustment for relevant confounders.

Treatment and Consequences

The possibility of acquiring a new infection strengthens the case for accurately staging and treating HCV before transplantation when treatment is feasible. Active chronic infection requires assessment of both hepatic and extrahepatic effects; liver fibrosis may be evaluated by biopsy or noninvasive methods such as FibroScan. Antiviral treatment before transplantation may also reduce the risk of post-transplant HCV-related glomerular disease, although its benefits for graft and patient survival had not been proven in the cited evidence.

Pretransplant treatment is not universally possible. Interferon-based therapy can produce adverse events, requires a prolonged course, has a substantial nonresponse rate, is expensive, and may require removal from the waiting list during treatment. Some end-stage renal disease patients refuse treatment, withdraw from it, or fail to respond. For such patients, transplantation may still offer a more favorable course than remaining on dialysis, and an HCV-positive kidney may provide a way to shorten the waiting period. The decision therefore balances the possibility of reinfection or superinfection against dialysis mortality, waiting-list deterioration, organ scarcity, and the risks of antiviral therapy.

HCV-related immune-complex disease can emerge in renal allografts. HCV-infected recipients are susceptible to de novo membranoproliferative glomerulonephritis, sometimes associated with type II mixed cryoglobulinemia. Clinical manifestations may include hypertension, microscopic hematuria, proteinuria, renal dysfunction, and occasionally nephrotic syndrome. Biopsy can show mesangial proliferation, double contours, and IgM and C3 deposits; electron microscopy may be required to distinguish membranoproliferative glomerulonephritis from transplant glomerulopathy, and the two lesions can coexist. In this setting, a new viral exposure is not an abstract laboratory event: it may add another source of immune injury to an already vulnerable graft.

Significance for Organ Allocation

HCV reinfection or superinfection exposes the limits of a simple positive-versus-negative classification. A recipient may be anti-HCV positive without active viremia, RNA positive without protection from another genotype, or cured before transplantation while remaining vulnerable to a new exposure. Organ allocation must therefore combine antibody testing, RNA testing, genotype information, liver staging, and realistic assessment of treatment options.

The concept also sits within a wider institutional chain of classification and access. Screening determines whether a candidate is placed on hold, monitored, treated, or referred for liver–kidney transplantation; donor testing determines whether an organ is discarded or offered; and genotype comparison shapes the conditions under which an HCV-positive kidney may be used. Because donated HCV-positive kidneys were reported to be 2.60 times more likely to be discarded than HCV-negative kidneys, careful recognition of superinfection risk can support informed use without pretending that prior infection supplies immunity. The governing principle is not that HCV-positive organs are harmless, but that their risks can be made more explicit and more manageable when viral status, genotype, liver disease, and the costs of continued dialysis are considered together.